Welcome to our dedicated page for Nano-X Imaging news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging stock.
NANO-X IMAGING LTD reports news on an integrated medical imaging and healthcare services platform built around Nanox.ARC multisource digital tomosynthesis systems, AI and software solutions, cloud-based workflow tools, remote radiology access, health information technology and a marketplace model. Company updates commonly cover U.S. commercialization, distribution agreements, clinical collaborations and regulatory clearances tied to Nanox.ARC and related imaging capabilities.
Recurring financial and operating news also includes results from teleradiology services, imaging products and services, AI and software activity, and the completed addition of Nanox Health IT. The company frames its commercial activity around broader access to 3D imaging and preventive-care workflows across clinical settings.
Nanox (NASDAQ:NNOX) will present new clinical data on its Nanox.AI cardiac solution HealthCCSng at the SCCT 2026 meeting in San Diego, July 9-12, 2026.
Highlights include initial multi-site AI INFORM trial results, a coronary calcium agreement analysis, and a sponsored session on aortic valve calcification.
Nanox (NASDAQ:NNOX) reported Q1 2026 revenue of $4.3M, up from $2.8M a year earlier, driven mainly by teleradiology and AI/software solutions. GAAP gross loss was $2.6M, with non-GAAP gross loss of $0.2M. Net loss reached $14.3M. Cash and deposits fell to $44.2M, with negative operating cash flow of $14.0M and an estimated $27M cash (net of a short-term loan) at release date, leading management to state there is substantial doubt about continuing as a going concern. The company withdrew its 2026 revenue target, will stop giving annual revenue guidance, has about 40 systems in deployment and distribution agreements for about 360 Capex systems over 2–3 years.
Nanox (Nasdaq:NNOX) will report first quarter 2026 financial results for the period ended March 31, 2026, before market open on June 25, 2026.
Management will host a conference call and live webcast at 8:30 a.m. ET to review results and provide a business update.
Nanox (NASDAQ:NNOX) signed an exclusive distribution agreement with Top Med to deploy its Nanox.ARC imaging system and platform in Peru under a capex model.
Initial plans call for six Nanox.ARC systems, pending required permits, with a pilot phase followed by a possible broader rollout.
Nano X Imaging (NASDAQ: NNOX) said its U.S. unit Nanox Impact signed a distribution agreement with NuvioDx to support deployment of Nanox.ARC systems across clinical sites in multiple states. The Nanox.ARC is an FDA-cleared multisource digital tomosynthesis system that aims to enable 3D imaging at lower cost and reduced radiation dose versus traditional CT.
The deal expands Nanox’s 2026 U.S. distribution framework and channel partner strategy to broaden regional market access and sustained system utilization.
Nanox (NASDAQ:NNOX) announced that Nanox Impact signed a U.S. distribution agreement with Radiology Oncology Systems to roll out the Nanox.ARC across U.S. clinical settings. The Nanox.ARC is an FDA-cleared multisource digital tomosynthesis system intended to expand 3D imaging access with lower dose and cost.
The agreement leverages Radiology Oncology Systems’ distribution and service network to support planned deployments in oncology-adjacent and other clinical environments.
Nano-X Imaging (NASDAQ:NNOX) signed a commercial agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems over three years, including 60 systems in year one. The Nanox.ARC is an FDA-cleared multisource digital tomosynthesis system said to offer 3D imaging at lower cost and reduced radiation versus traditional CT.
Howard will market and deploy systems across its national healthcare and public sector channels, targeting underserved customer segments and leveraging its nationwide sales and service infrastructure.
NANO-X IMAGING (NASDAQ: NNOX) reported $3.7M revenue for Q4 2025 and a $33.4M net loss, driven largely by a $17.5M impairment tied to a South Korea manufacturing restructuring. The company closed the Nanox Health IT acquisition, signed U.S. distribution agreements (including 300 systems with Howard) and has ~36 systems in deployment.
Guy Nathanzon is appointed CFO effective August 1, 2026; restructuring charges total approximately $18.0M.
Nanox (Nasdaq: NNOX) announced on April 16, 2026 that its Nanox.ARC X 3D digital tomosynthesis system won the Red Dot Award: Product Design 2026. The award recognizes the system's compact, single-unit design, plug-and-play installation, and potential for broader clinical deployment. The device will be featured in Red Dot exhibitions and yearbook, increasing global visibility for the design created with TAGA Innovations.
The company emphasized the product's reduced footprint versus CT, simplified workflow, and remote upgrade capability as enablers for use in smaller imaging centers and outpatient clinics.
Nanox (Nasdaq: NNOX) announced a clinical collaboration with Meir Medical Center on April 14, 2026 to evaluate the Nanox.ARC multisource digital tomosynthesis system for emergency orthopedic imaging.
The IRB-approved study will compare Nanox.ARC to conventional radiography and CT for fracture detection, focusing on diagnostic confidence, speed, and lower radiation dose to support broader clinical adoption.